IL108713A - Stabilization of polypeptides treated with organics using inert carriers - Google Patents

Stabilization of polypeptides treated with organics using inert carriers

Info

Publication number: IL108713A
Authority: IL; Israel
Prior art keywords: polypeptide; organic solvent; excipient; methylene chloride; formulations
Prior art date: 1993-02-23

Application number

IL10871394A

Other languages

English (en)

Hebrew (he)

Other versions

IL108713A0 (en

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-02-23

Filing date

1994-02-20

Publication date

1999-12-22

1994-02-20 Application filed by Genentech Inc filed Critical Genentech Inc

1994-05-30 Publication of IL108713A0 publication Critical patent/IL108713A0/xx

1999-12-22 Publication of IL108713A publication Critical patent/IL108713A/en

Links

102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 137
108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 137
229920001184 polypeptide Polymers 0.000 title claims abstract description 136
239000003960 organic solvent Substances 0.000 title claims abstract description 48
230000006641 stabilisation Effects 0.000 title abstract description 17
238000011105 stabilization Methods 0.000 title abstract description 17
239000000203 mixture Substances 0.000 claims abstract description 122
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 49
238000000034 method Methods 0.000 claims abstract description 46
229920005862 polyol Polymers 0.000 claims abstract description 22
150000003077 polyols Chemical class 0.000 claims abstract description 22
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 204
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 50
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 35
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 35
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 35
239000000872 buffer Substances 0.000 claims description 30
239000013011 aqueous formulation Substances 0.000 claims description 19
229920000642 polymer Polymers 0.000 claims description 16
238000013270 controlled release Methods 0.000 claims description 7
239000007864 aqueous solution Substances 0.000 claims description 6
239000011159 matrix material Substances 0.000 claims description 6
230000000087 stabilizing effect Effects 0.000 claims description 6
239000003755 preservative agent Substances 0.000 claims description 5
102000018997 Growth Hormone Human genes 0.000 claims description 3
108010051696 Growth Hormone Proteins 0.000 claims description 3
238000005538 encapsulation Methods 0.000 claims description 3
239000000122 growth hormone Substances 0.000 claims description 3
239000008363 phosphate buffer Substances 0.000 claims description 3
230000002335 preservative effect Effects 0.000 claims description 3
102000008070 Interferon-gamma Human genes 0.000 claims description 2
108010074328 Interferon-gamma Proteins 0.000 claims description 2
229940044627 gamma-interferon Drugs 0.000 claims description 2
239000008362 succinate buffer Substances 0.000 claims description 2
229940074410 trehalose Drugs 0.000 claims 7
238000009472 formulation Methods 0.000 description 102
239000000854 Human Growth Hormone Substances 0.000 description 63
102000002265 Human Growth Hormone Human genes 0.000 description 63
108010000521 Human Growth Hormone Proteins 0.000 description 63
235000018102 proteins Nutrition 0.000 description 46
102000004169 proteins and genes Human genes 0.000 description 46
108090000623 proteins and genes Proteins 0.000 description 46
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 45
229930195725 Mannitol Natural products 0.000 description 45
239000000594 mannitol Substances 0.000 description 45
235000010355 mannitol Nutrition 0.000 description 45
239000004094 surface-active agent Substances 0.000 description 27
238000011084 recovery Methods 0.000 description 25
229920000136 polysorbate Polymers 0.000 description 24
239000007787 solid Substances 0.000 description 20
239000000243 solution Substances 0.000 description 20
239000007921 spray Substances 0.000 description 19
238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 17
239000004005 microsphere Substances 0.000 description 16
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 15
230000036425 denaturation Effects 0.000 description 14
238000004925 denaturation Methods 0.000 description 14
229920001223 polyethylene glycol Polymers 0.000 description 14
238000012360 testing method Methods 0.000 description 14
229920002134 Carboxymethyl cellulose Polymers 0.000 description 13
239000002202 Polyethylene glycol Substances 0.000 description 13
239000003814 drug Substances 0.000 description 13
239000000178 monomer Substances 0.000 description 12
239000001768 carboxy methyl cellulose Substances 0.000 description 11
235000010948 carboxy methyl cellulose Nutrition 0.000 description 11
239000008112 carboxymethyl-cellulose Substances 0.000 description 11
238000002835 absorbance Methods 0.000 description 10
229940079593 drug Drugs 0.000 description 10
238000004108 freeze drying Methods 0.000 description 10
230000002776 aggregation Effects 0.000 description 9
238000004220 aggregation Methods 0.000 description 9
238000001035 drying Methods 0.000 description 8
230000008569 process Effects 0.000 description 8
239000002904 solvent Substances 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
239000000539 dimer Substances 0.000 description 7
238000001542 size-exclusion chromatography Methods 0.000 description 7
238000001694 spray drying Methods 0.000 description 7
239000000725 suspension Substances 0.000 description 7
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 6
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 6
108010010803 Gelatin Proteins 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
235000012538 ammonium bicarbonate Nutrition 0.000 description 6
239000001099 ammonium carbonate Substances 0.000 description 6
229920001577 copolymer Polymers 0.000 description 6
239000000839 emulsion Substances 0.000 description 6
239000008273 gelatin Substances 0.000 description 6
229920000159 gelatin Polymers 0.000 description 6
235000019322 gelatine Nutrition 0.000 description 6
235000011852 gelatine desserts Nutrition 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
238000002156 mixing Methods 0.000 description 6
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000000265 homogenisation Methods 0.000 description 5
238000011068 loading method Methods 0.000 description 5
239000000843 powder Substances 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
229940024606 amino acid Drugs 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
239000012071 phase Substances 0.000 description 4
229920000747 poly(lactic acid) Polymers 0.000 description 4
229920000570 polyether Polymers 0.000 description 4
238000013268 sustained release Methods 0.000 description 4
239000012730 sustained-release form Substances 0.000 description 4
229920002307 Dextran Polymers 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000013583 drug formulation Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000012537 formulation buffer Substances 0.000 description 3
239000011521 glass Substances 0.000 description 3
239000002502 liposome Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
239000002736 nonionic surfactant Substances 0.000 description 3
239000002245 particle Substances 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
229940074404 sodium succinate Drugs 0.000 description 3
ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
150000005846 sugar alcohols Chemical class 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
239000004215 Carbon black (E152) Substances 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
108010000817 Leuprolide Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
238000011161 development Methods 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
239000005038 ethylene vinyl acetate Substances 0.000 description 2
239000011536 extraction buffer Substances 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
150000002430 hydrocarbons Chemical class 0.000 description 2
239000000017 hydrogel Substances 0.000 description 2
230000003993 interaction Effects 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
239000003446 ligand Substances 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
229920001983 poloxamer Polymers 0.000 description 2
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
238000000527 sonication Methods 0.000 description 2
238000005507 spraying Methods 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
238000003860 storage Methods 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
102000004411 Antithrombin III Human genes 0.000 description 1
108090000935 Antithrombin III Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
239000004381 Choline salt Substances 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
108010010369 HIV Protease Proteins 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000013566 Plasminogen Human genes 0.000 description 1
108010051456 Plasminogen Proteins 0.000 description 1
239000004721 Polyphenylene oxide Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
238000011481 absorbance measurement Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000007605 air drying Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229960003767 alanine Drugs 0.000 description 1
229940124277 aminobutyric acid Drugs 0.000 description 1
WGYFACNYUJGZQO-UHFFFAOYSA-N aminomethanetriol Chemical class NC(O)(O)O WGYFACNYUJGZQO-UHFFFAOYSA-N 0.000 description 1
238000012436 analytical size exclusion chromatography Methods 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
229960005348 antithrombin iii Drugs 0.000 description 1
UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
229960001950 benzethonium chloride Drugs 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
150000001722 carbon compounds Chemical class 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
235000019417 choline salt Nutrition 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000007429 general method Methods 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229960002743 glutamine Drugs 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000013101 initial test Methods 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960004338 leuprorelin Drugs 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229940087857 lupron Drugs 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
229940100630 metacresol Drugs 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
238000003801 milling Methods 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
229940116406 poloxamer 184 Drugs 0.000 description 1
-1 poloxamer 184 or 188 Polymers 0.000 description 1
229940044519 poloxamer 188 Drugs 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920002643 polyglutamic acid Polymers 0.000 description 1
229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
210000004896 polypeptide structure Anatomy 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229950008882 polysorbate Drugs 0.000 description 1
229940068977 polysorbate 20 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
238000004321 preservation Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
238000005086 pumping Methods 0.000 description 1
150000003248 quinolines Chemical class 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000012085 test solution Substances 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Compositions Of Macromolecular Compounds (AREA)

IL10871394A 1993-02-23 1994-02-20 Stabilization of polypeptides treated with organics using inert carriers IL108713A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US2142193A	1993-02-23	1993-02-23

Publications (2)

Publication Number	Publication Date
IL108713A0 IL108713A0 (en)	1994-05-30
IL108713A true IL108713A (en)	1999-12-22

Family

ID=21804127

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10871394A IL108713A (en)	1993-02-23	1994-02-20	Stabilization of polypeptides treated with organics using inert carriers

Country Status (17)

Country	Link
US (3)	US5589167A (de)
EP (1)	EP0686045B1 (de)
JP (1)	JP3698721B2 (de)
CN (1)	CN1108823C (de)
AT (1)	ATE197550T1 (de)
AU (1)	AU685784B2 (de)
CZ (1)	CZ296649B6 (de)
DE (1)	DE69426292T2 (de)
DK (1)	DK0686045T3 (de)
ES (1)	ES2153418T3 (de)
GR (1)	GR3035383T3 (de)
IL (1)	IL108713A (de)
NZ (1)	NZ262634A (de)
PT (1)	PT686045E (de)
RU (1)	RU2143889C1 (de)
WO (1)	WO1994019020A1 (de)
ZA (1)	ZA941239B (de)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0679088B1 (de)	1992-09-29	2002-07-10	Inhale Therapeutic Systems	Pulmonale abgabe von aktiven fragmenten des parathormons
ATE416755T1 (de)	1994-03-07	2008-12-15	Nektar Therapeutics	Verfahren und zusammensetzung für die pulmonale darreichung von insulin
US6290991B1 (en)	1994-12-02	2001-09-18	Quandrant Holdings Cambridge Limited	Solid dose delivery vehicle and methods of making same
US6586006B2 (en)	1994-08-04	2003-07-01	Elan Drug Delivery Limited	Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
JPH10508744A (ja)	1994-09-22	1998-09-02	クオドラントホールディングスケンブリッジリミテッド	運動競技の間の水分補給および栄養摂取の用途のための組成物ならびにその製造法
PT831787E (pt) *	1995-06-07	2002-02-28	Alkermes Inc	Composicao para libertacao sustentada da hormona de crescimento humano
US6964771B1 (en)	1995-06-07	2005-11-15	Elan Drug Delivery Limited	Method for stably incorporating substances within dry, foamed glass matrices
ES2434840T3 (es) *	1995-07-27	2013-12-17	Genentech, Inc.	Formulación de proteína liofilizada isotónica estable
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
US6685940B2 (en) *	1995-07-27	2004-02-03	Genentech, Inc.	Protein formulation
JP2014148555A (ja) *	1995-07-27	2014-08-21	Genentech Inc	タンパク質の処方
US5762961A (en) *	1996-02-09	1998-06-09	Quadrant Holdings Cambridge Ltd.	Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US5958455A (en) *	1996-02-09	1999-09-28	Quadrant Holdings Cambridge Ltd	Oral solid dosage forms, methods of making same and compositions thereof
AUPN801296A0 (en) *	1996-02-12	1996-03-07	Csl Limited	Stabilised growth hormone formulation and method of preparation thereof
US6190702B1 (en)	1996-03-28	2001-02-20	Takeda Chemical Industries, Ltd.	Sustained-released material prepared by dispersing a lyophilized polypeptide in an oil phase
US6632648B1 (en)	1996-05-14	2003-10-14	Elan Drug Delivery Limited	Methods of terminal sterilization of fibrinogen
US5932547A (en) *	1996-07-03	1999-08-03	Alza Corporation	Non-aqueous polar aprotic peptide formulations
US5916582A (en) *	1996-07-03	1999-06-29	Alza Corporation	Aqueous formulations of peptides
AU737664B2 (en) *	1996-07-03	2001-08-30	Alza Corporation	Non-aqueous protic peptide formulations
US5861174A (en) *	1996-07-12	1999-01-19	University Technology Corporation	Temperature sensitive gel for sustained delivery of protein drugs
US5981489A (en) *	1996-07-18	1999-11-09	Alza Corporation	Non-aqueous protic peptide formulations
US6468782B1 (en)	1996-12-05	2002-10-22	Quadrant Healthcare (Uk) Limited	Methods of preserving prokaryotic cells and compositions obtained thereby
WO1998027980A2 (en)	1996-12-20	1998-07-02	Takeda Chemical Industries, Ltd.	Method of producing a sustained-release preparation
US6991790B1 (en) *	1997-06-13	2006-01-31	Genentech, Inc.	Antibody formulation
US6663899B2 (en)	1997-06-13	2003-12-16	Genentech, Inc.	Controlled release microencapsulated NGF formulation
US6113947A (en) *	1997-06-13	2000-09-05	Genentech, Inc.	Controlled release microencapsulated NGF formulation
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
GEP20022707B (en) *	1997-07-18	2002-06-25	Infimed Inc Us	Biodegrading Macromers for the Controlled Release of Biologically Active Substances
US6565885B1 (en)	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
US6309623B1 (en)	1997-09-29	2001-10-30	Inhale Therapeutic Systems, Inc.	Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en)	1997-09-29	2006-07-27	Nektar Therapeutics	Pulmonary delivery particles comprising water insoluble or crystalline active agents
SE512663C2 (sv)	1997-10-23	2000-04-17	Biogram Ab	Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
AU2945199A (en) *	1998-03-18	1999-10-11	Ronai, Peter	Amorphous glasses for stabilising sensitive products
ATE367828T1 (de) *	1998-04-03	2007-08-15	Novartis Vaccines & Diagnostic	Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel
CA2329010A1 (en) *	1998-04-17	1999-10-28	Angiogenix Incorporated	Therapeutic angiogenic factors and methods for their use
US6284282B1 (en) *	1998-04-29	2001-09-04	Genentech, Inc.	Method of spray freeze drying proteins for pharmaceutical administration
US6190701B1 (en)	1999-03-17	2001-02-20	Peter M. Ronai	Composition and method for stable injectable liquids
GB9910975D0 (en) *	1999-05-13	1999-07-14	Univ Strathclyde	Rapid dehydration of proteins
US6566329B1 (en) *	1999-06-28	2003-05-20	Novo Nordisk A/S	Freeze-dried preparation of human growth hormone
US6102896A (en) *	1999-09-08	2000-08-15	Cambridge Biostability Limited	Disposable injector device
US7582311B1 (en)	1999-10-15	2009-09-01	Genentech, Inc.	Injection vehicle for polymer-based formulations
US7651703B2 (en) *	1999-10-15	2010-01-26	Genentech, Inc.	Injection vehicle for polymer-based formulations
WO2001058428A1 (en) *	2000-02-10	2001-08-16	Alkermes Controlled Therapeutics, Inc.	Method of preparing a sustained release composition
US6992065B2 (en)	2000-04-19	2006-01-31	Genentech, Inc.	Sustained release formulations
PT1280520E (pt)	2000-05-10	2014-12-16	Novartis Ag	Pós à base de fosfolípidos para administração de fármacos
US8404217B2 (en)	2000-05-10	2013-03-26	Novartis Ag	Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en)	2000-05-10	2011-01-18	Novartis Ag	Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6653062B1 (en)	2000-07-26	2003-11-25	Wisconsin Alumni Research Foundation	Preservation and storage medium for biological materials
CA2418960A1 (en) *	2000-08-07	2002-02-14	Inhale Therapeutic Systems, Inc.	Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
US6824822B2 (en) *	2001-08-31	2004-11-30	Alkermes Controlled Therapeutics Inc. Ii	Residual solvent extraction method and microparticles produced thereby
EP1449523A1 (de) *	2000-10-13	2004-08-25	Cambridge Biostability Ltd	Zusammensetzung und Verfahren für injizierbare Flüssigkeiten
ATE420630T1 (de) *	2000-11-29	2009-01-15	Itoham Foods Inc	Pulverzubereitungen und verfahren zu ihrer herstellung
US20040022861A1 (en) *	2001-01-30	2004-02-05	Williams Robert O.	Process for production of nanoparticles and microparticles by spray freezing into liquid
ATE427760T1 (de) *	2001-02-23	2009-04-15	Genentech Inc	Erodierbare polymere zur injektion
JP4460892B2 (ja) *	2001-06-21	2010-05-12	ジェネンテックインコーポレイテッド	徐放性組成物
GB0116074D0 (en) *	2001-06-29	2001-08-22	Univ Strathclyde	Nanoparticle structures
GB2391480B (en)	2002-08-05	2007-02-28	Caretek Medical Ltd	Drug delivery system
GB2379390B (en) *	2001-09-11	2005-01-26	Caretek Medical Ltd	A novel drug delivery technology
US7615234B2 (en) *	2001-09-11	2009-11-10	Glide Pharmaceutical Technologies Limited	Drug delivery technology
PT1458360E (pt)	2001-12-19	2011-07-13	Novartis Ag	Derivados de indole como agonistas do recetor s1p1
EP1493015A4 (de) *	2002-04-05	2006-01-04	Powerzyme Inc	Analytsensor
AU2003230320A1 (en) *	2002-05-09	2003-11-11	Peptron Co., Ltd	Sustained release formulation of protein and preparation method thereof
CN100444848C (zh) *	2002-09-27	2008-12-24	特里梅里斯公司	HIV gp41-衍生肽的改善用药的药物组合物
US7045552B2 (en) *	2002-09-27	2006-05-16	Trimeris, Inc.	Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
WO2004035762A2 (en)	2002-10-17	2004-04-29	Alkermes Controlled Therapeutics, Inc. Ii	Microencapsulation and sustained release of biologically active polypeptides
RU2357750C2 (ru) *	2002-12-31	2009-06-10	Элтус Фармасьютикалз Инк.	Кристаллы человеческого гормона роста и способы их получения
JP2006523609A (ja) *	2002-12-31	2006-10-19	アルタスファーマシューティカルズインコーポレイテッド	タンパク質結晶およびイオン性ポリマーの複合体
US20040197413A1 (en) *	2003-04-04	2004-10-07	Genteric, Inc.	Spray dry coacervation systems and methods
DE10320609A1 (de) *	2003-05-08	2004-12-02	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Sprühgefriergranulate mit verbesserter Homogenität der Eigenschaftsverteilung und Verfahren zu deren Herstellung
US7090433B2 (en) *	2003-10-07	2006-08-15	Steve Searby	Underground cable laying apparatus
US20050095320A1 (en) *	2003-10-29	2005-05-05	Richard Botteri	[An Isotonic Sports Drink for Female Athletes Fortified with Iron, Calcium and Essential Vitamins for Use in Rehydration and Nutrition During Execise and Competition]
US20050100636A1 (en) *	2003-11-10	2005-05-12	Megan Botteri	[A Low-Calorie Sports Drink For Physically Active Women That is Fortified with Iron, Calcium and Essential Vitamins for Use in Rehydration and Replacing Electrolytes Lost During Periods of Physical Activity]
AU2004313242A1 (en) *	2004-01-07	2005-07-28	Trimeris, Inc.	HIV gp41 HR2-derived synthetic peptides, and their use in therapy to inhibit transmission of human immunodeficiency virus
US7456254B2 (en) *	2004-04-15	2008-11-25	Alkermes, Inc.	Polymer-based sustained release device
US8617613B2 (en)	2004-04-15	2013-12-31	Alkermes Pharma Ireland Limited	Polymer-based sustained release device
JP2007277094A (ja) *	2004-06-29	2007-10-25	Chemo Sero Therapeut Res Inst	改変ダニ主要アレルゲン含有医薬組成物
US7133638B2 (en) *	2004-11-18	2006-11-07	Xerox Corporation	Scanning method and an image-processing device including the same
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
GB2422784A (en) *	2005-02-07	2006-08-09	Caretek Medical Ltd	Disposable assembly comprising a needle or stylet
ES2569409T3 (es) *	2005-03-08	2016-05-10	Pfizer Products Inc.	Composiciones de anticuerpo anti-CTLA-4
CN100336557C (zh) *	2005-05-11	2007-09-12	北京双鹭药业股份有限公司	一种生长抑素的水溶液制剂、其制备方法及应用
CN100342909C (zh) *	2005-05-11	2007-10-17	北京双鹭药业股份有限公司	一种胸腺素α1的水溶液制剂、其制备方法及应用
CN100337684C (zh) *	2005-05-11	2007-09-19	北京双鹭药业股份有限公司	一种胸腺五肽的水溶液制剂、其制备方法及应用
GB0517688D0 (en) *	2005-08-31	2005-10-05	Cambridge Biostability Ltd	Improvements in the stabilisation of biological materials
US9309316B2 (en) *	2005-12-20	2016-04-12	Bristol-Myers Squibb Company	Stable subcutaneous protein formulations and uses thereof
US8476239B2 (en) *	2005-12-20	2013-07-02	Bristol-Myers Squibb Company	Stable protein formulations
US20090023629A1 (en) *	2005-12-23	2009-01-22	Altus Pharmaceuticals Inc.	Compositions comprising polycation-complexed protein crystals and methods of treatment using them
TWI341844B (en)	2006-02-02	2011-05-11	Trimeris Inc	Hiv fusion inhibitor peptides with improved biological properties
ATE455153T1 (de) *	2006-03-13	2010-01-15	Becker & Co Naturinwerk	Kollagenpulver und auf kollagen basierende thermoplastische zusammensetzung zur herstellung von formkörpern
EP2359808B1 (de)	2006-08-09	2013-05-22	Intarcia Therapeutics, Inc	Osmotisches Verabreichungssystem mit Kolbenanordnung
US20100028451A1 (en)	2006-09-26	2010-02-04	Trustees Of Tufts College	Silk microspheres for encapsulation and controlled release
US8946200B2 (en) *	2006-11-02	2015-02-03	Southwest Research Institute	Pharmaceutically active nanosuspensions
AU2007234612B2 (en) *	2006-12-14	2013-06-27	Johnson & Johnson Regenerative Therapeutics, Llc	Protein stabilization formulations
CA2672284C (en) *	2006-12-18	2014-08-26	Altus Pharmaceuticals Inc.	Human growth hormone formulations
EP2111228B1 (de) *	2007-02-02	2011-07-20	Bristol-Myers Squibb Company	10Fn3 Domain zur Behandlung von Krankheiten begleitet von unerwünschter Angiogenese
HUE026001T2 (en)	2007-02-05	2016-04-28	Apellis Pharmaceuticals Inc	Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
CA2682848A1 (en) *	2007-04-03	2008-10-16	Trimeris, Inc.	Novel formulations for delivery of antiviral peptide therapeutics
WO2008133908A2 (en)	2007-04-23	2008-11-06	Intarcia Therapeutics, Inc.	Suspension formulations of insulinotropic peptides and uses thereof
CN101677944A (zh) *	2007-06-01	2010-03-24	诺沃-诺迪斯克有限公司	稳定的非含水药物组合物
US7678764B2 (en)	2007-06-29	2010-03-16	Johnson & Johnson Regenerative Therapeutics, Llc	Protein formulations for use at elevated temperatures
JP5323832B2 (ja)	2007-08-07	2013-10-23	アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー	酸性水溶液中にｇｄｆ−５を含むタンパク質製剤
CN101874038A (zh) *	2007-09-25	2010-10-27	特里梅里斯公司	治疗性抗-hiv肽的合成方法
CA2726861C (en)	2008-02-13	2014-05-27	Intarcia Therapeutics, Inc.	Devices, formulations, and methods for delivery of multiple beneficial agents
US8404850B2 (en) *	2008-03-13	2013-03-26	Southwest Research Institute	Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
HUE032284T2 (en)	2008-03-18	2017-09-28	Novo Nordisk As	Protease-stabilized, acylated insulin analogues
BRPI0911048A2 (pt) *	2008-04-14	2015-12-29	Atrm Llc	formulações líquidas tamponadas de gdf-5
US8722706B2 (en) *	2008-08-15	2014-05-13	Southwest Research Institute	Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en) *	2008-10-03	2012-11-13	Southwest Research Institute	Modified calcium phosphate nanoparticle formation
UA106606C2 (uk) *	2009-03-16	2014-09-25	Родія Оперейшнс	Стабілізована біоцидна композиція
WO2011005381A2 (en)	2009-06-01	2011-01-13	Trustees Of Tufts College	Vortex-induced silk fibroin gelation for encapsulation and delivery
RU2431496C2 (ru) *	2009-09-15	2011-10-20	Общество С Ограниченной Ответственностью "Герофарм"	Инъекционная лекарственная форма для лечения острого ишемического инсульта и черепно-мозговой травмы, способ ее изготовления и применение
RU2547990C2 (ru)	2009-09-28	2015-04-10	Интарсия Терапьютикс, Инк.	Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US9028873B2 (en) *	2010-02-08	2015-05-12	Southwest Research Institute	Nanoparticles for drug delivery to the central nervous system
PT3345615T (pt)	2010-03-01	2020-01-17	Bayer Healthcare Llc	Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
WO2011109691A2 (en)	2010-03-05	2011-09-09	Trustees Of Tufts College	Silk-based ionomeric compositions
GB201004072D0 (en)	2010-03-11	2010-04-28	Turzi Antoine	Process, tube and device for the preparation of wound healant composition
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN107233569B (zh)	2011-10-25	2021-08-31	普罗西纳生物科学有限公司	抗体制剂和方法
WO2013096835A1 (en) *	2011-12-23	2013-06-27	Abbvie Inc.	Stable protein formulations
EP2807177B1 (de)	2012-01-27	2019-11-13	The Regents of The University of California	Stabilisierung von biomolekülen anhand von zuckerpolymeren
CN104364260B (zh)	2012-04-11	2017-02-22	诺和诺德股份有限公司	胰岛素制剂
WO2014035798A1 (en)	2012-08-30	2014-03-06	Sanofi	Silk lyogels for sustained release of protein therapeutics and methods of making and uses
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
US8613919B1 (en)	2012-08-31	2013-12-24	Bayer Healthcare, Llc	High concentration antibody and protein formulations
CN106456695B (zh) *	2014-04-28	2019-11-12	卫材R&D管理有限公司	Hgf的冻干配制品
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RU2730996C2 (ru)	2015-06-03	2020-08-26	Интарсия Терапьютикс, Инк.	Системы установки и извлечения имплантата
JP2017110001A (ja) *	2015-12-16	2017-06-22	株式会社資生堂	タブレット型凍結乾燥化粧料
KR102275262B1 (ko)	2016-03-17	2021-07-12	에자이 알앤드디 매니지먼트 가부시키가이샤	활성 간세포 성장 인자(hgf)를 생성하는 방법
KR102574993B1 (ko)	2016-05-16	2023-09-06	인타르시아 세라퓨틱스 인코포레이티드	글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
WO2018017610A1 (en) *	2016-07-18	2018-01-25	Tissuegen, Inc.	Methods and compositions for maintaining the conformation and structural integrity of biomolecules
PE20210857A1 (es)	2016-12-16	2021-05-18	Novo Nordisk As	Composiciones farmaceuticas que contienen insulina
JP7286542B2 (ja)	2017-01-03	2023-06-05	インターシアセラピューティクス，インコーポレイティド	Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
JP6404405B1 (ja) *	2017-06-14	2018-10-10	株式会社資生堂	タブレット型凍結乾燥化粧料
TWI787186B (zh) *	2017-06-19	2022-12-21	日商資生堂股份有限公司	錠型凍結乾燥化妝料
US20210145705A1 (en) *	2017-06-19	2021-05-20	Shiseido Company, Ltd.	Tablet-type freeze-dried cosmetic
CN108169499A (zh) *	2017-11-30	2018-06-15	成都斯马特科技有限公司	一种基于生化试剂盘进行凝血分析的方法
EP3849579A4 (de) *	2018-09-14	2022-06-15	Cara Therapeutics, Inc.	Orale formulierungen von kappa-opioid-rezeptoragonisten
CA3127191A1 (en)	2019-01-21	2020-07-30	Eclipse Medcorp, Llc	Methods, systems and apparatus for separating components of a biological sample
MX2022004999A (es)	2019-10-31	2022-07-27	Eclipse Medcorp Llc	Sistemas, metodos y aparatos para separar componentes de una muestra.
KR20240135062A (ko) *	2022-02-01	2024-09-10	오큘라 테라퓨틱스, 인코포레이티드	생물 제제용 제어 방출 임플란트 및 상응하는 치료 방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3664963A (en) *	1969-10-22	1972-05-23	Balchem Corp	Encapsulation process
IT1103817B (it) *	1978-06-27	1985-10-14	Guaber Spa	Composizione deodorante granulare per posacenere
DE2916711A1 (de) *	1979-04-25	1980-11-06	Behringwerke Ag	Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
JPS60100516A (ja) *	1983-11-04	1985-06-04	Takeda Chem Ind Ltd	徐放型マイクロカプセルの製造法
EP0193917A3 (de) *	1985-03-06	1987-09-23	American Cyanamid Company	Wasserdispersible und wasserlösliche Polymerzusammensetzungen für parenterale Anwendung
JPH0779694B2 (ja) *	1985-07-09	1995-08-30	カドラントバイオリソ−シズリミテツド	蛋白質および同類品の保護
GB8604983D0 (en) *	1986-02-28	1986-04-09	Biocompatibles Ltd	Protein preservation
US4816568A (en) *	1986-05-16	1989-03-28	International Minerals & Chemical Corp.	Stabilization of growth hormones
US4962091A (en) *	1986-05-23	1990-10-09	Syntex (U.S.A.) Inc.	Controlled release of macromolecular polypeptides
JP2526589B2 (ja) *	1986-08-08	1996-08-21	武田薬品工業株式会社	ペプチド含有マイクロカプセルおよびその製造法
US5312745A (en) *	1987-06-18	1994-05-17	Chromogenix Ab	Determination of components active in proteolysis
EP0303746B2 (de) *	1987-08-21	1998-12-02	Mallinckrodt Group Inc.	Stabilisierung von Wachstumshormonen
WO1989003671A1 (fr) *	1987-10-29	1989-05-05	Dainippon Pharmaceutical Co., Ltd.	Preparation a liberation entretenue
GB8801338D0 (en) *	1988-01-21	1988-02-17	Quadrant Bioresources Ltd	Preservation of viruses
SU1599019A1 (ru) *	1988-02-08	1990-10-15	Всесоюзный научно-исследовательский институт химии и технологии лекарственных средств	Способ получени лиофилизата
JP2670680B2 (ja) *	1988-02-24	1997-10-29	株式会社ビーエムジー	生理活性物質含有ポリ乳酸系微小球およびその製造法
AT392079B (de) *	1988-03-11	1991-01-25	Voest Alpine Ind Anlagen	Verfahren zum druckvergasen von kohle fuer den betrieb eines kraftwerkes
US5096885A (en) *	1988-04-15	1992-03-17	Genentech, Inc.	Human growth hormone formulation
US5039540A (en) *	1989-08-14	1991-08-13	Neophore Technologies, Inc.	Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5032405A (en) *	1989-09-27	1991-07-16	Warner-Lambert Company	Oral pharmaceutical composition for acid sensitive proteinaceous agents
US5312705A (en) *	1990-07-27	1994-05-17	Matsushita Electric Industrial Co., Ltd.	Photosensitive materials for electrophotography having a double-layer structure of a charge generation layer and a charge transport layer
WO1992014449A1 (en) *	1991-02-20	1992-09-03	Nova Pharmaceutical Corporation	Controlled release microparticulate delivery system for proteins
FR2673843B1 (fr) *	1991-03-14	1995-01-13	Centre Nat Rech Scient	Composition pharmaceutique implantable, bioresorbable a base de poly(acide lactique), destinee a mettre en óoeuvre une antibiotherapie interne locale.
EP0724433B1 (de) *	1993-10-22	1998-12-30	Genentech, Inc.	Verfahren zur herstellung von mikrospharen mit einer wirbelschichtstufe
DE69431404T2 (de) *	1993-10-22	2003-04-30	Genentech Inc., San Francisco	Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
ATE223702T1 (de) *	1993-10-22	2002-09-15	Genentech Inc	Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien

1994
- 1994-02-17 AU AU62412/94A patent/AU685784B2/en not_active Expired
- 1994-02-17 PT PT94909647T patent/PT686045E/pt unknown
- 1994-02-17 US US08/256,187 patent/US5589167A/en not_active Expired - Lifetime
- 1994-02-17 RU RU95118293A patent/RU2143889C1/ru active
- 1994-02-17 NZ NZ262634A patent/NZ262634A/en not_active IP Right Cessation
- 1994-02-17 CZ CZ0212795A patent/CZ296649B6/cs not_active IP Right Cessation
- 1994-02-17 JP JP51910094A patent/JP3698721B2/ja not_active Expired - Lifetime
- 1994-02-17 ES ES94909647T patent/ES2153418T3/es not_active Expired - Lifetime
- 1994-02-17 DE DE69426292T patent/DE69426292T2/de not_active Expired - Lifetime
- 1994-02-17 CN CN94191235A patent/CN1108823C/zh not_active Expired - Lifetime
- 1994-02-17 WO PCT/US1994/001666 patent/WO1994019020A1/en not_active Ceased
- 1994-02-17 DK DK94909647T patent/DK0686045T3/da active
- 1994-02-17 AT AT94909647T patent/ATE197550T1/de active
- 1994-02-17 EP EP94909647A patent/EP0686045B1/de not_active Expired - Lifetime
- 1994-02-20 IL IL10871394A patent/IL108713A/en not_active IP Right Cessation
- 1994-02-23 ZA ZA941239A patent/ZA941239B/xx unknown
1995
- 1995-05-15 US US08/442,241 patent/US5753219A/en not_active Expired - Lifetime
1996
- 1996-09-24 US US08/719,196 patent/US5804557A/en not_active Expired - Lifetime
2001
- 2001-02-07 GR GR20010400210T patent/GR3035383T3/el unknown

Also Published As

Publication number	Publication date
ZA941239B (en)	1995-08-23
AU6241294A (en)	1994-09-14
DK0686045T3 (da)	2001-03-05
CZ212795A3 (en)	1996-02-14
US5589167A (en)	1996-12-31
WO1994019020A1 (en)	1994-09-01
EP0686045B1 (de)	2000-11-15
CN1108823C (zh)	2003-05-21
IL108713A0 (en)	1994-05-30
US5804557A (en)	1998-09-08
CN1118143A (zh)	1996-03-06
RU2143889C1 (ru)	2000-01-10
ATE197550T1 (de)	2000-12-15
GR3035383T3 (en)	2001-05-31
ES2153418T3 (es)	2001-03-01
US5753219A (en)	1998-05-19
NZ262634A (en)	1997-02-24
CZ296649B6 (cs)	2006-05-17
AU685784B2 (en)	1998-01-29
JP3698721B2 (ja)	2005-09-21
PT686045E (pt)	2001-04-30
DE69426292T2 (de)	2001-05-17
EP0686045A1 (de)	1995-12-13
DE69426292D1 (de)	2000-12-21
JPH08507064A (ja)	1996-07-30

Legal Events

Date	Code	Title
2000-06-01	FF	Patent granted
2000-08-31	KB	Patent renewed
2004-03-28	KB	Patent renewed
2008-03-23	KB	Patent renewed
2012-02-29	KB	Patent renewed
2014-09-30	EXP	Patent expired

Publication	Publication Date	Title
US5589167A (en)	1996-12-31	Excipient stabilization of polypeptides treated with organic solvents
AU2003217367B2 (en)	2005-09-08	Polymer-based compositions for sustained release
Cleland et al.	1997	Recombinant human growth hormone poly (lactic-co-glycolic acid) microsphere formulation development
DE69713378T2 (de)	2003-01-30	Stabile protein- und nukleinsäure- formulierungen unter verwendung nichtwässriger, wasserfreier, aprotischer, hydrophober, nichtpolarer vehikel mit geringer reaktivität
US20030138491A1 (en)	2003-07-24	Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
EP3434263B1 (de)	2020-07-15	Verfahren zur herstellung eines mikropartikels mit verzögerter freisetzung
CA2172508C (en)	2005-08-23	Method for preparing microspheres comprising a fluidized bed drying step
HUP0200202A2 (hu)	2002-05-29	Stabilis, nemvizes egyfázisú, viszkózus vivőanyagok és ilyen vivőanyagokat hasznosító összetételek
US8025900B2 (en)	2011-09-27	Sustained release composition of protein drug
CA2154164C (en)	2005-11-22	Excipient stabilization of polypeptides treated with organic solvents
CN101022833B (zh)	2012-01-04	甘油二棕榈酸硬脂酸酯用于提高皮下或肌肉注射制剂中的蛋白质活性成分的生物利用度的用途